Cg Oncology Inc (CGON)

NASD · Healthcare · Biotechnology · USA

Cg Oncology Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene, an investigational oncolytic immunotherapy for non-muscle invasive bladder cancer. The company is evaluating the therapy through multiple clinical trials in patients with high-risk and intermediate-risk disease, including those unresponsive to BCG treatment, and has submitted a regulatory application for its initial indication.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Cg Oncology Inc stock.

Our verdict on CGON

Overvalued: intrinsic value $8.07 per share, market price $78.94, margin of safety -878.6% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $8.07; the price of $78.94 is 879% above that value.

ETFs with the most weight in CGON

17 more funds hold it; the full list is part of the paid plan.

More on CGON

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than CGON in Biotechnology

105 more in this industry show a wider margin of safety.

Is CGON undervalued or overvalued?

CGON is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $8.07; the price of $78.94 is 879% above that value.

What is the intrinsic value of CGON?

$8.07 per share (as of the 2026-11-17 close), against a market price of $78.94. That is a margin of safety of -878.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.